Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Abbisko Out-Licenses Rights to Non-Oncology Indications for CSF-1R Inhibitor

Abbisko Therapeutics of  Shanghai  out-licensed greater China rights for ABSK021 to Sperogenix ( Shanghai ) MedTech. Sperogenix will develop the candidate only for non-oncology rare neurological diseases indications in China , with amyotrophic lateral sclerosis (ALS) as the first target. Abbisko will receive upfront and milestone payments as well as royalties on annual net sales from Sperogenix, while it continues to hold rights to the candidate for oncology diseases. ABSK021 is an oral, selective colony-stimulating factor 1 receptor (CSF-1R) antagonist. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.